



**5<sup>th</sup> isirv-AVG Conference**  
**Prevention and Treatment of RVIs: Antivirals, Traditional Therapies and Host-Directed Interventions**

**14-16 June 2017**  
**Regal East Asia Hotel, Shanghai, China**

**Draft Programme**

|                          |   |
|--------------------------|---|
| <b>Wednesday 14 June</b> |   |
| <b>08:00-08:20</b>       | <b>Opening &amp; Welcome</b><br>HongZhou Lu, Fudan University & SPHCC, Shanghai, China (Chair Organising Committee) & Alan Hay, Francis Crick Institute, London, UK (Chair isirv-AVG)   |
| <b>08:20-09:00</b>       | <b>Session 1</b><br><b>Chairs:</b> HongZhou Lu, Fudan University & SPHCC, Shanghai, China (Chair Organising Committee) & Alan Hay, Francis Crick Institute, London, UK (Chair isirv-AVG)<br><br><b>Keynote Lecture</b><br><b>Zoonotic Respiratory Viral Threats at the Animal-Human Interface</b><br><i>Malik Peiris, University of Hong Kong, Hong Kong SAR, China</i>   |
| <b>09:00-10:40</b>       | <b>Session 2: Symposium on Novel Coronaviruses</b><br><b>Chairs:</b> Malik Peiris, University of Hong Kong, Hong Kong SAR, China and Chen Wang, China-Japan Friendship Hospital, Beijing, China (TBC)<br><br>Insights from Pre-clinical Models of MERS and SARS<br><i>Ralph Baric, University of North Carolina, Chapel Hill, North Carolina, USA</i><br><br>Clinical Features and the Virologic Course of MERS<br><i>Myoung-don Oh, Seoul National University, Seoul, Korea</i><br><br>Coronavirus Immunology<br><i>Jincun Zhao, State Key Lab of Respiratory Disease, Guangzhou, China</i><br><br>Advances in Developing Vaccines and Therapeutics against MERS-CoV<br><i>Shibo Jiang, Fudan University, Shanghai, China</i>  |
| <b>10:40 -11:10</b>      | <b>Refreshments</b>   |
| <b>11:10 -12:45</b>      | <b>Session 3: Oral Abstract Session 1- Emerging threats</b><br><b>Chairs:</b> HongZhou Lu, Fudan University & SPHCC, Shanghai, China and Menno de Jong, University of Amsterdam, Amsterdam, Holland<br><br><b>Introductory talk-</b> Lessons from Nosocomial Outbreaks of MERS<br><i>Sang Won Park, Seoul National University College of Medicine, Seoul, Korea</i><br><br>Human Adenovirus Type 80: A Novel Adenovirus Causing ARDS and Disseminated Infection with Fatal Outcome<br><i>Barbara Rath, Vienna Vaccine Safety Initiative, Berlin, Germany</i><br><br>Epidemiological and Clinical Characteristics of Enterovirus D68 (EV-D68) Infection Among Children Aged Less Than Five Years in the Philippines<br><i>Mariko Saito-Obata, Tohoku University Graduate School of Medicine, Sendai, Japan</i> |

|              |  |
|--------------|--|
|              | <p>Detection of Influenza A(H1N1)pdm09 Viruses Exhibiting Enhanced Cross-Resistance to Oseltamivir and Peramivir in Japan<br/><i>Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan</i></p> <p>Clinical and Virological Outcomes Upon Emergence of Oseltamivir-Resistant Influenza A Viruses in Treated Individuals: The IRIS Study<br/><i>Rueshandra Roosenhoff, Erasmus MC, Rotterdam, Netherlands</i></p> <p>Update and Consolidation of WHO Standard Guideline for the Clinical Management of Severe Influenza Infections<br/><i>Paula Lister, Great Ormond Street Hospital, London, UK</i></p>  |
| 12:45 -13:45 | <b>Lunchtime Seminar – Sponsored by Anhui Jiren Pharmaceutical Co., LTD</b>  |
| 13:45 -15:20 | <p><b>Session 4: Avian A(H7N9) influenza</b><br/><b>Chairs:</b> Yuelong Shu, China CDC, Beijing, China and David Hui, Chinese University of Hong Kong, Hong Kong SAR, China</p> <p>H7N9 Infection in Humans: Susceptibility and Immune Responses<br/><i>Yuanlin Song, Zhongshan Hospital, China</i></p> <p>H7N9 Disease and Pathogenesis<br/><i>Lei Zhou, China CDC, Beijing, China</i></p> <p>Virological Update<br/><i>Yuelong Shu, China CDC, Beijing, China</i></p> <p>Antiviral Treatment and Resistance<br/><i>Junwen Hu, Shanghai Fudan University, China</i></p>   |
| 15:20-15:50  | <b>Refreshments</b>  |
| 15:50-17:55  | <p><b>Session 5: Oral Abstract Session 2- RVI Diagnosis and Treatment</b><br/><b>Chairs:</b> Yi-Wei Tang, Memorial Sloan Kettering, New York, USA and Maria Zambon, Public Health England, London, UK</p> <p><b>Introductory Talk-</b> Advances in RVI Molecular Diagnostics<br/><i>Yi-Wei Tang, Memorial Sloan Kettering, New York, USA</i></p> <p>Routine Molecular Point-of-Care Testing for Respiratory Viruses in Adults Presenting to Hospital with Acute Respiratory Illness: Results of a Large, Pragmatic, Randomised Controlled Trial<br/><i>Tristan Clark, University of Southampton, Southampton, UK</i></p> <p>A Simple Tool-CLAP to Assess the Severity of Influenza A (H7N9) Viral Pneumonia<br/><i>Yeming Wang, Xuan Wu Hospital Capital Medical University, Beijing, China</i></p> <p>Investigation of Antibody Dynamics in the Randomized Study with Japanese Pediatric Patients with Influenza A Virus Infection After Treatment of Four Neuraminidase Inhibitors (Part 2)<br/><i>Nobuo Hirotsu, Hirotsu Clinic, Kawasaki, Japan</i></p> <p>A Randomized Controlled Trial on Adjunctive Macrolide Treatment in Adults Hospitalized with Influenza<br/><i>Nelson Lee, The Chinese University of Hong Kong, Hong Kong SAR, China</i></p> <p>Broad Spectrum In Vitro and In Vivo Activity of RO-7, a Novel Inhibitor of the Influenza Virus PA Endonuclease<br/><i>Jeremy Jones, St. Jude Children's Research Hospital, Memphis, TN, USA</i></p> <p>The Topaz Trial: A Phase 2B Study of Pimodivir (JNJ-63623872 or JNJ-872; formerly VX-787) as Monotherapy or in Combination With Oseltamivir in the Treatment of Acute Uncomplicated Seasonal Influenza<br/><i>Lorant Leopold, Janssen, Titusville, New Jersey, USA</i></p> <p>IRC003: A Randomized Study of Combination Antivirals for the Treatment of Influenza<br/><i>John Beigel, NIAID, Bethesda, MD, USA</i></p> |

|                         |  |
|-------------------------|--|
| 18:30-21:00             | Conference Networking Dinner   |
| <b>Thursday 15 June</b> |  |
| 08:00-08:40             | <p><b>Session 6:</b><br/> <b>Chairs:</b> Bin Cao and Yinzhong Shen</p> <p><b>Keynote Lecture</b><br/> <b>Burden of Respiratory Virus Diseases in China</b><br/> <i>Hongjie Yu, Chinese Centre for Disease Control, Beijing, China</i></p>  |
| 08:40-10:00             | <p><b>Session 7: Oral Abstract Session 3 - RVI Impact and CAP</b><br/> <b>Chairs:</b> Zhancheng Gao, Peking University, Beijing, China (TBC) and Myoung-don Oh, Seoul National University, Seoul, Korea</p> <p><b>Introductory Talk:</b> Chinese guidelines for CAP 2016<br/> <i>Jieming Qu, Shanghai Ruijin Hospital, Shanghai, China</i></p> <p>Comparison of Self-Reported Contact Patterns Between Hospital-Based Healthcare Workers and Working Adults From the General Population and its Implications for Infectious Disease Transmission<br/> <i>Lili Jiang, National University of Singapore, Singapore</i></p> <p>Difference in Clinical Presentation of Human Metapneumovirus Group-A Lineages Associated with Paediatric ARI Hospitalizations in Central Vietnam during 2007-2015<br/> <i>Keisuke Yoshihara, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan</i></p> <p>The Genomic and Epidemiological Dynamics of Respiratory Syncytial Virus in New South Wales, Australia Between 2010-2016<br/> <i>John-Sebastian Eden, The University of Sydney, Sydney, NSW, Australia</i></p> <p>Etiology and Incidence of Severe Acute Respiratory Infection Among Hospitalized Patients in Antananarivo, Madagascar, 2014-2016<br/> <i>Norosoa Razanajatovo, Institut Pasteur de Madagascar, Antananarivo, Madagascar</i></p> |
| 10:00 -10:30            | Refreshments   |
| 10:30-12:00             | <p><b>Session 8: Oral Abstract Session 4- Pathogenesis of SARI</b><br/> <b>Chairs:</b> Ralph Baric, University of North Carolina, Chapel Hill, NC, USA and Peter Openshaw Imperial College, London, United Kingdom</p> <p><b>Introductory Talk-</b> What Part do Bacteria Play in Severe Influenza?<br/> <i>Peter Openshaw, Imperial College, London, United Kingdom</i></p> <p>Severity and Phase Linked Virus Specific CD4 and CD8T Cell Responses in Human pH1N1 Infection<br/> <i>Hui Li, Capital Medical University, Beijing, China</i></p> <p>AIM2 Inflammasome is Critical for Influenza Induced Lung Injury and Mortality<br/> <i>Jieru Wang, University of Pittsburgh, Pittsburgh, USA</i></p> <p>Identification of DDX19B as an Essential Host Factor for Uncoating Step During Influenza Virus Entry<br/> <i>Jihye Lee, Institut Pasteur Korea, Republic of Korea</i></p> <p>Studies to Gain Insights into Drug Resistance of Influenza A(H7N9) Viruses<br/> <i>Larisa Gubareva, Centers for Disease Control and Prevention, Atlanta, GA, USA</i></p>   |
| 12:00 – 13:00           | Lunchtime Seminar – TBC  |

|                             |   |
|-----------------------------|---|
| <p><b>13:00 -15:00</b></p>  | <p><b>Session 9: Symposium on RVI Therapeutics</b><br/> <b>Chairs:</b> George Gao, Chinese Academy of Sciences, Beijing, China &amp; Amy Krafft, NIAID, Bethesda, Maryland, USA,</p> <p>Understanding Antiviral Targets<br/> <i>Yoshi Kawaoka, University of Wisconsin, Madison Wisconsin USA and University of Tokyo, Tokyo, Japan</i></p> <p>Prospects for Antivirals for RSV Disease<br/> <i>Peter Openshaw, Imperial College, London, United Kingdom</i></p> <p>Novel RSV Inhibitor AK0529: Update on Clinical Development<br/> <i>Stephen Toovey, Chief Medical Officer, Ark Biosciences</i></p> <p>Usefulness of Probiotics for RVI Mitigation<br/> <i>Lisa Lehtoranta, DuPont Nutrition &amp; Health, Kantvik, Finland</i></p> <p>Which Traditional Chinese Medicines are Most Beneficial?<br/> <i>Bin Cao, China-Japan Friendship Hospital, Beijing, China</i></p>  |
| <p><b>15:00 – 15:30</b></p> | <p><b>Refreshments</b></p>  |
| <p><b>15:30 – 17:45</b></p> | <p><b>Session 10: Oral Abstract Session 5 - Short Presentations on Developments of Influenza Antivirals</b><br/> <b>Chairs:</b> Frederick Hayden, University of Virginia School of Medicine, Charlottesville, USA and Aeron Hurt, WHO Influenza Collaborating Centre, Melbourne, Australia</p> <p>Introductory Talk: Building The Pre-Clinical Pipeline<br/> <i>Amy Krafft, NIAID, Bethesda, Maryland, USA</i></p> <p><b>Invited Topics:</b><br/> PB2 Inhibitor JNJ-872<br/> <i>Lorant Leopold, Janssen, Titusville, New Jersey, USA</i></p> <p>Cap-dependent Endonuclease Inhibitor S-033188<br/> <i>Keiko Kawaguchi, Shionogi, Osaka, Japan</i></p> <p>MHAA4549A Monoclonal<br/> <i>Man Wah Tan, Genentech, South San Francisco, California, USA</i></p> <p>VIS410 Monoclonal<br/> <i>Jose Trevejo, Visterra, Cambridge, Massachusetts, USA</i></p> <p>Experience with Favipiravir in Phase 3 and Implications for Future Studies<br/> <i>Carol Epstein Medivector, Boston Massachusetts, USA</i></p> <p>Nitazoxanide: A First-in-Class Indirect-Acting Antiviral for Treatment of Respiratory Virus Infections<br/> <i>Jean-Francois Rossignol, Romark, Morristown, New Jersey, USA</i></p> <p>IV Zanamivir<br/> <i>Sumita Roy-Ghanta, GSK, Philadelphia, Pennsylvania, USA</i></p> <p>Umifenovir (Arbidol) – Antiviral Drug Against Influenza Viruses<br/> <i>Irina Leneva, Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia</i></p> <p>Oral Danirixin (GSK1325756)<br/> <i>Sumita Roy-Ghanta, GSK, Philadelphia, Pennsylvania, USA</i></p> <p>Developing Therapeutic Human Antibodies from Transchromosomal (Tc) Bovine to Treating Influenza Infection<br/> <i>Hua Wu, SAb Biotherapeutics, Sioux Falls, SD, USA</i></p> |
| <p><b>17:45 – 19:30</b></p> | <p><b>Poster Session Reception – Sponsored by Gilead Sciences, Inc</b></p>  |

|                       |  |
|-----------------------|--|
| <b>Friday 16 June</b> |  |
| <b>08:00 – 08:45</b>  | <p><b>Session 11:</b><br/> <b>Chairs:</b> Arnold Monto, University of Michigan School of Public Health, Ann Arbor, USA &amp; Yinzhong Shen, Fudan University and SPHCC, Shanghai, China</p> <p><b>Keynote Lecture</b><br/> <b>Advances in Vaccines for Respiratory Viral Infections</b><br/> <i>Barney Graham, Vaccine Research Center, NIAID, Bethesda, Maryland, USA</i></p>   |
| <b>08:45-10:30</b>    | <p><b>Session 12: Oral Abstract Session 6- Vaccines and Preventive Strategies</b><br/> <b>Chairs:</b> Barney Graham, Vaccine Research Center, NIAID, Bethesda, Maryland, USA and Arnold Monto, University of Michigan School of Public Health, Ann Arbor, USA</p> <p><b>Introductory Talk- Protective Immunity During Natural H7N9 Infection in Humans</b><br/> <i>Jianqing Xu, Shanghai Public Health Clinical Center, Shanghai, China</i></p> <p>Natural H7N9 Infection in Humans Boosts Cross-Group Stalk-Specific Antibody Responses<br/> <i>Lu Liu, Shanghai Public Health Clinical Center, Shanghai, China</i></p> <p>A Single IM Dose of a Plant-Made VLP Vaccine Bearing the H1 Hemagglutinin Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Challenge<br/> <i>Breanna Hodgins, McGill University, Montreal, Quebec, Canada</i></p> <p>An mRNA-Based Technology for the Next Generation of Prophylactic Influenza Vaccines<br/> <i>Susanne Rauch, CureVac AG, Tuebingen, Germany</i></p> <p>Development and Validation of a Non-Egg-Adapted Wild-Type Influenza A H3N2 Strain (A/Belgium/4217/2015 (H3N2)) As Challenge Agent for Human Volunteer Challenge Studies<br/> <i>Martin Schutten, Clinical Virology and Diagnostics, Noord-Holland, Netherlands</i></p> <p>A Treg Cell Based Novel RSV Vaccine<br/> <i>Bing Wang, Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University, Shanghai, China</i></p> <p>Evaluation of the Effectiveness of Oseltamivir Against Influenza Variants with the H275Y Neuraminidase Mutation in Ferrets<br/> <i>Ding Oh, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia</i></p> |
| <b>10:30 – 11:00</b>  | <b>Refreshments</b>  |
| <b>11:00-13:00</b>    | <p><b>Session 13: Discussion on Clinical Research Issues</b><br/> <b>Chairs:</b> Kimberly Armstrong, BARDA, Washington, USA and Michael Ison, Northwestern University, Chicago, Illinois, USA</p> <p>Updating the WHO Influenza Research Agenda<br/> <i>Nahoko Shindo, WHO, Geneva, Switzerland</i></p> <p>What Endpoints Make Sense in Clinical Trials of Severe Influenza and Related Illnesses?<br/> <i>Menno de Jong, University of Amsterdam, Amsterdam, Holland</i></p> <p>Developing Influenza Therapeutics - A European Regulator's Perspective<br/> <i>Regine Lehnert, BfArM, Germany</i></p> <p>Feasible or Infeasible? Investigational Drug Monotherapy for Patients Hospitalised with Laboratory-Confirmed Influenza<br/> <i>Kimberley Armstrong, BARDA, Washington, DC, USA</i></p> <p><b>Roundtable Discussion</b></p>   |

|              |   |
|--------------|---|
| 13:00 -14:00 | Lunchtime Seminar – TBC   |
| 14:00 -16:00 | <p><b>Session 14: Symposium on Issues in Clinical Management</b><br/> <b>Chairs:</b> Zhan Cheng Gao, Peking University, Beijing, China (TBC) and Norio Sugaya, Keiyu Hospital, Yokohama, Japan</p> <p>Under-Recognized and Unusual Presentations of Influenza<br/> <i>William Fischer, University of North Carolina, Chapel Hill, North Carolina, USA</i></p> <p>Managing RVIs in Transplant Recipients<br/> <i>Michael Ison, Northwestern University, Chicago, Illinois, USA</i></p> <p>Corticosteroids, Statins, and Other Adjunctive Therapies in SARI<br/> <i>David Hui, Chinese University of Hong Kong, Hong Kong SAR, China</i></p> <p>Mutagenesis analysis to identify determinants for neuraminidase inhibitor resistance in influenza viruses of N8 and N9 subtypes<br/> <i>Hui-Ling Yen, University of Hong Kong, Hong Kong SAR, China</i></p> <p><b>Q &amp; A Panel</b></p> |
| 16:00-16:30  | Closing Remarks   |